Enasidenib adult dosage is usually 100 mg once daily, and should be continued until disease progression or unacceptable toxicity occurs. For specific dosage of Enasidenib, please follow your doctor's instructions.
Indications for Enasidenib
For the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-2 (IDH2) mutation detected in blood or bone marrow by an FDA-approved test.
Enasidenib Dosing Guide
1. Recommended Dosage
Oral, 100 mg once daily, with or without food.
2. Duration of Treatment
(1) Should be continued until disease progression or unacceptable toxicity.
(2) For patients without disease progression or unacceptable toxicity, treatment should be given for at least 6 months to allow sufficient time for clinical response observation.
Enasidenib Use in Special Populations
1. Renal Impairment
Data not yet established.
2. Hepatic Impairment
Data not yet established.
3. Pediatric Use
Safety and efficacy have not been established in patients under 18 years of age.
4. Dialysis
Data not yet established.
